Liver Transplant Criteria and Downstaging in Hepatocellular Carcinoma

No, this is not typical of the Pringle manoeuvre itself. Needing a stent afterwards points to bile duct involvement: a narrowed biliary confluence after a right hepatectomy, a bile leak that progressed to a stricture after a hepaticojejunostomy, or compromised duct vascularity following preoperative radiotherapy. The Pringle manoeuvre alone may raise liver enzymes, but it should not cause obstructive jaundice.

For HCC after resection or an interventional procedure, MRI is favoured over repeated CT scans, both to limit cumulative radiation and contrast exposure and because MRI catches smaller lesions earlier, while they are still resectable or eligible for salvage transplant. Cholangiocarcinoma follow-up similarly relies on CT or MRI rather than ultrasound, alongside tumour markers, AFP and PIVKA-II for HCC, CA19-9 for cholangiocarcinoma.

Intent comes first. Even in India, transplant is offered at only a handful of government centres, with growth coming mainly from the private sector. Beyond intent, a new programme needs mentorship from teams already trained in transplant so that skills transfer gradually, buy-in across radiology, anaesthesia, critical care and hepatology rather than a purely surgeon-driven effort, and infrastructure including a strong interventional radiology service, phasic CT and MRI, and an apheresis machine for ABO-incompatible transplants. Management has to be fully behind the programme, because it takes far more time and effort than routine GI or hepatobiliary surgery.

Dr. George asked to review the actual scan before a specific recommendation, but for a resectable tumour around 3 to 3.5 centimetres, his general advice was not to force a diagnosis upfront: resect with a clear margin and send the specimen for histopathology. At that size, liver function or parenchymal loss is unlikely to be a concern, so surgery can proceed before, rather than after, a biopsy.

Hepatocellular carcinomas develop on a cirrhotic liver, which is like a fertile field: removing one tumour by resection or ablation does not remove the underlying tendency of that liver to produce another. Because the diseased liver stays in place after resection or ablation, these patients carry a higher ongoing risk of new tumours. A transplant removes the whole diseased liver and replaces it with one that does not carry that risk, which is why upfront transplant can be the better option even when a tumour looks resectable.

The Milan criteria qualify a patient for transplant if they have a single tumour under 5 centimetres, or up to three tumours each under 3 centimetres. Patients meeting these criteria have excellent outcomes.

The University of California, San Francisco (UCSF) criteria extend eligibility to a single tumour up to 6.5 centimetres, or three tumours each up to 4.5 centimetres with a total diameter under 8 centimetres, with survival outcomes comparable to Milan. Many patients who fall outside Milan can still be transplanted successfully under UCSF.

Portal venous invasion is graded from VP1 to VP4 depending on which branch is involved: VP1 is a segmental branch, VP2 is a right anterior or posterior sectoral branch, VP3 is the right or left main branch, and VP4 is the main portal vein itself.

Downstaging typically starts with TACE for the primary tumour, sometimes across multiple sessions, with SBRT added for a portal vein tumour thrombus. The goal is stable disease sustained over 12 weeks, meaning no disease outside the liver, a meaningful drop in tumour markers, and no progression within the liver, at which point the patient becomes eligible for transplant.

Not entirely. Recurrence rates after downstaging run somewhat higher than for patients who qualified for transplant from the outset, though the alternative for patients who cannot reach stable disease, best supportive care, carries a much higher mortality over time.